Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.
Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants. During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ...
Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...
Credit: Getty Images. Evidence suggests that patent ductus arteriosus comprises anywhere from 5% to 10% of all congenital heart disease. Although the majority of congenital heart diseases (CHD) are ...
A small but rigorous randomized trial suggests paracetamol may be a feasible alternative to ibuprofen for late PDA treatment, while underscoring the need for larger multicenter studies to guide ...
The Society for Cardiovascular Angiography & Interventions (SCAI) has published a new position statement that provides best-practice guidance for the treatment of patent ductus arteriosus (PDA) using ...
“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...
Medical device and healthcare company Abbott arranged to have their canine and kid patients treated for patent ductus ...
Once a PDA is suspected or confirmed, the 2 main questions are (1) how to treat and (2) when to treat a particular infant This clinical controversy recently was the subject of an excellent systematic ...
Objective: To provide commentary and reviews and brief discussions in controversial or innovative recent advances in neonatal pharmacotherapy. To discuss cutting edge drug delivery systems that may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results